

Notes:


1. The above audited financial results were reviewed by the audit committee and taken on record by the board of directors at its meeting held on May 24, 2013.
2. The board of directors have recommended a final dividend of Rs. 2.25/-per equity share (225%) for the financial year 2012-2013.
3. Pursuant to the approval of Shareholders for Buyback vide postal ballot voting on August 17, 2012, the Company has bought back 1,533,432 equity shares of Re.1 each during the quarter ended March 31, 2013. All the equity shares have been extinguished as of date. Further 1,338,538 equity shares were bought back from April 01, 2013 till the date of this board meeting making it a total buyback of 3,425,970 equity shares.
4. The figures for the quarter ended March 31, 2013 are the balancing figures between audited figures in respect of the full financial year up to March 31, 2013 and the unaudited published year-to-date figures up to December 31, 2012, which was subject to Limited Review, being the date of the end of the third quarter of the said financial year.
5. During the current year, Company has made revision in the estimated useful life of certain class of fixed assets which has resulted in higher charge of depreciation cost of Rs. 803.79 lacs.
6. "Other expenses" includes provision/(Reversal) of diminution in value of the current investments as follows:

(Rs. in lacs)				
Quarter Ended 31/03/2013	Quarter Ended 31/12/2012	Quarter Ended 31/03/2012	Year Ended 31/03/2013	Year Ended 31/03/2012
135.34	88.04	(353.61)	4.77	192.42

7. The Company has only one segment of activity namely "Pharmaceuticals".
8. Figures for the previous period have been restated/reclassified wherever necessary to conform to the current period's presentation.

Place: Mumbai
Date: May 24, 2013

For and on behalf of the Board


Mohan A. Chandavarkar
Chairman and Managing Director